1
|
Meissner WG, Frasier M, Gasser T, Goetz
CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, et
al: Priorities in Parkinson's disease research. Nat Rev Drug
Discov. 10:377–393. 2011. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Noelker C, Bacher M, Gocke P, Wei X,
Klockgether T, Du Y and Dodel R: The flavanoide caffeic acid
phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity.
Neurosci Lett. 383:39–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
3
|
Jankovic J: Parkinson's disease: Clinical
features and diagnosis. J Neurol Neurosurg Psychiatry. 79:368–376.
2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Engler H, Doenlen R, Riether C, Engler A,
Niemi MB, Besedovsky HO, del Rey A, Pacheco-López G, Feldon J and
Schedlowski M: Time-dependent alterations of peripheral immune
parameters after nigrostriatal dopamine depletion in a rat model of
Parkinson's disease. Brain Behav Immun. 23:518–526. 2009.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Dardiotis E, Xiromerisiou G,
Hadjichristodoulou C, Tsatsakis AM, Wilks MF and Hadjigeorgiou GM:
The interplay between environmental and genetic factors in
Parkinson's disease susceptibility: The evidence for pesticides.
Toxicology. 307:17–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Hirsch EC, Hunot S, Faucheux B, Agid Y,
Mizuno Y, Mochizuki H, Tatton WG, Tatton N and Olanow WC:
Dopaminergic neurons degenerate by apoptosis in Parkinson's
disease. Mov Disord. 14:383–385. 1999. View Article : Google Scholar : PubMed/NCBI
|
7
|
Miller RL, James-Kracke M, Sun GY and Sun
AY: Oxidative and inflammatory pathways in Parkinson's disease.
Neurochem Res. 34:55–65. 2009. View Article : Google Scholar
|
8
|
Shimura H, Hattori N, Kubo S, Mizuno Y,
Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, et
al: Familial Parkinson disease gene product, parkin, is a
ubiquitin-protein ligase. Nat Genet. 25:302–305. 2000. View Article : Google Scholar : PubMed/NCBI
|
9
|
Dugan LL, Tian L, Quick KL, Hardt JI,
Karimi M, Brown C, Loftin S, Flores H, Moerlein SM, Polich J, et
al: Carboxyfullerene neuroprotection postinjury in Parkinsonian
nonhuman primates. Ann Neurol. 76:393–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Cassarino DS, Parks JK, Parker WD Jr and
Bennett JP Jr: The parkinsonian neurotoxin MPP+ opens
the mitochondrial permeability transition pore and releases
cytochrome c in isolated mitochondria via an oxidative mechanism.
Biochim Biophys Acta. 1453:49–62. 1999. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lotharius J, Dugan LL and O'Malley KL:
Distinct mechanisms underlie neurotoxin-mediated cell death in
cultured dopaminergic neurons. J Neurosci. 19:1284–1293.
1999.PubMed/NCBI
|
12
|
Lee CS, Han ES, Jang YY, Han JH, Ha HW and
Kim DE: Protective effect of harmalol and harmaline on MPTP
neurotoxicity in the mouse and dopamine-induced damage of brain
mitochondria and PC12 cells. J Neurochem. 75:521–531. 2000.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Lee CS, Park SY, Ko HH, Song JH, Shin YK
and Han ES: Inhibition of MPP+-induced mitochondrial
damage and cell death by trifluoperazine and W-7 in PC12 cells.
Neurochem Int. 46:169–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
14
|
Rojas P and Rios C: Increased striatal
lipid peroxidation after intracerebroventricular MPP+
administration to mice. Pharmacol Toxicol. 72:364–368. 1993.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Abdel-Salam OM: Drugs used to treat
Parkinson's disease, present status and future directions. CNS
Neurol Disord Drug Targets. 7:321–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wattanathorn J, Chonpathompikunlert P,
Muchimapura S, Priprem A and Tankamnerdthai O: Piperine, the
potential functional food for mood and cognitive disorders. Food
Chem Toxicol. 46:3106–3110. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Shrivastava P, Vaibhav K, Tabassum R, Khan
A, Ishrat T, Khan MM, Ahmad A and Islam F, Safhi MM and Islam F:
Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA
induced Parkinson's rat model. J Nutr Biochem. 24:680–687. 2013.
View Article : Google Scholar
|
18
|
Vijayakumar RS1, Surya D and Nalini N:
Antioxidant efficacy of black pepper (Piper nigrum L.) and piperine
in rats with high fat diet induced oxidative stress. Redox Rep.
9:105–110. 2004. View Article : Google Scholar : PubMed/NCBI
|
19
|
Bajad S, Bedi KL, Singla AK and Johri RK:
Antidiarrhoeal activity of piperine in mice. Planta Med.
67:284–287. 2001. View Article : Google Scholar : PubMed/NCBI
|
20
|
Bai YF and Xu H: Protective action of
piperine against experimental gastric ulcer. Acta Pharmacol Sin.
21:357–359. 2000.
|
21
|
Selvendiran K, Prince Vijeya Singh J and
Sakthisekaran D: In vivo effect of piperine on serum and tissue
glycoprotein levels in benzo(a)pyrene induced lung carcinogenesis
in Swiss albino mice. Pulm Pharmacol Ther. 19:107–111. 2006.
View Article : Google Scholar
|
22
|
Gupta SK, Bansal P, Bhardwaj RK and
Velpandian T: Comparative anti-nociceptive, anti-inflammatory and
toxicity profile of nimesulide vs. nimesulide and piperine
combination. Pharmacol Res. 41:657–662. 2000. View Article : Google Scholar : PubMed/NCBI
|
23
|
Atal CK, Dubey RK and Singh J: Biochemical
basis of enhanced drug bioavailability by piperine: Evidence that
piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp
Ther. 232:258–262. 1985.PubMed/NCBI
|
24
|
Hu Y, Liao HB, Liu P, Guo DH and Wang YY:
Antidepressant effects of piperine and its neuroprotective
mechanism in rats. Zhong Xi Yi Jie He Xue Bao. 7:667–670. 2009.In
Chinese. View Article : Google Scholar : PubMed/NCBI
|
25
|
Chonpathompikunlert P, Wattanathorn J and
Muchimapura S: Piperine, the main alkaloid of Thai black pepper,
protects against neurodegeneration and cognitive impairment in
animal model of cognitive deficit like condition of Alzheimer's
disease. Food Chem Toxicol. 48:798–802. 2010. View Article : Google Scholar
|
26
|
Lee CS, Han ES and Kim YK: Piperine
inhibition of 1-methyl-4-phenylpyridinium-induced mitochondrial
dysfunction and cell death in PC12 cells. Eur J Pharmacol.
537:37–44. 2006. View Article : Google Scholar : PubMed/NCBI
|
27
|
Rozas G, López-Martín E, Guerra MJ and
Labandeira-García JL: The overall rod performance test in the
MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods.
83:165–175. 1998. View Article : Google Scholar : PubMed/NCBI
|
28
|
Kim SR, Chen X, Oo TF, Kareva T, Yarygina
O, Wang C, During M, Kholodilov N and Burke RE: Dopaminergic
pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann
Neurol. 70:110–120. 2011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kim SR, Kareva T, Yarygina O, Kholodilov N
and Burke RE: AAV transduction of dopamine neurons with
constitutively active Rheb protects from neurodegeneration and
mediates axon regrowth. Mol Ther. 20:275–286. 2012. View Article : Google Scholar :
|
30
|
Kim SR, Chung ES, Bok E, Baik HH, Chung
YC, Won SY, Joe E, Kim TH, Kim SS, Jin MY, et al: Prothrombin
kringle-2 induces death of mesencephalic dopaminergic neurons in
vivo and in vitro via microglial activation. J Neurosci Res.
88:1537–1548. 2010.
|
31
|
Burnette WN: 'Western blotting':
Electrophoretic transfer of proteins from sodium dodecyl sulfate -
polyacrylamide gels to unmodified nitrocellulose and radiographic
detection with antibody and radioiodinated protein A. Anal Biochem.
112:195–203. 1981. View Article : Google Scholar : PubMed/NCBI
|
32
|
Casani S, Gómez-Pastor R, Matallana E and
Paricio N: Antioxidant compound supplementation prevents oxidative
damage in a Drosophila model of Parkinson's disease. Free Radic
Biol Med. 61:151–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Block ML and Hong JS: Microglia and
inflammation-mediated neurodegeneration: Multiple triggers with a
common mechanism. Prog Neurobiol. 76:77–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
34
|
Wang T, Zhang W, Pei Z, Block M, Wilson B,
Reece JM, Miller DS and Hong JS: Reactive microgliosis participates
in MPP+-induced dopaminergic neurodegeneration: role of
67 kDa laminin receptor. FASEB J. 20:906–915. 2006. View Article : Google Scholar : PubMed/NCBI
|
35
|
Baillet A, Chanteperdrix V, Trocmé C,
Casez P, Garrel C and Besson G: The role of oxidative stress in
amyotrophic lateral sclerosis and Parkinson's disease. Neurochem
Res. 35:1530–1537. 2010. View Article : Google Scholar : PubMed/NCBI
|
36
|
Carvalho AN, Marques C, Rodrigues E,
Henderson CJ, Wolf CR, Pereira P and Gama MJ: Ubiquitin-proteasome
system impairment and MPTP-induced oxidative stress in the brain of
C57BL/6 wild-type and GSTP knockout mice. Mol Neurobiol.
47:662–672. 2013. View Article : Google Scholar
|
37
|
Jakowec MW and Petzinger GM:
1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-lesioned model of
parkinson's disease, with emphasis on mice and nonhuman primates.
Comp Med. 54:497–513. 2004.PubMed/NCBI
|
38
|
Sundström E, Fredriksson A and Archer T:
Chronic neurochemical and behavioral changes in MPTP-lesioned
C57BL/6 mice: a model for Parkinson's disease. Brain Res.
528:181–188. 1990. View Article : Google Scholar : PubMed/NCBI
|
39
|
Kurz MJ, Pothakos K, Jamaluddin S,
Scott-Pandorf M, Arellano C and Lau YS: A chronic mouse model of
Parkinson's disease has a reduced gait pattern certainty. Neurosci
Lett. 429:39–42. 2007. View Article : Google Scholar : PubMed/NCBI
|
40
|
Petroske E, Meredith GE, Callen S,
Totterdell S and Lau YS: Mouse model of Parkinsonism: a comparison
between subacute MPTP and chronic MPTP/probenecid treatment.
Neuroscience. 106:589–601. 2001. View Article : Google Scholar : PubMed/NCBI
|
41
|
Matheus FC, Aguiar AS Jr, Castro AA,
Villarinho JG, Ferreira J, Figueiredo CP, Walz R, Santos AR, Tasca
CI and Prediger RD: Neuroprotective effects of agmatine in mice
infused with a single intranasal administration of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behav Brain
Res. 235:263–272. 2012. View Article : Google Scholar : PubMed/NCBI
|
42
|
Hutter-Saunders JA, Gendelman HE and
Mosley RL: Murine motor and behavior functional evaluations for
acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
intoxication. J Neuroimmune Pharmacol. 7:279–288. 2012. View Article : Google Scholar :
|
43
|
Whishaw IQ, Li K, Whishaw PA, Gorny B and
Metz GA: Use of rotorod as a method for the qualitative analysis of
walking in rat. J Vis Exp. 22:10302008.
|
44
|
Emre M, Ford PJ, Bilgic B and Uc EY:
Cognitive impairment and dementia in Parkinson's disease: practical
issues and management. Mov Disord. 29:663–672. 2014. View Article : Google Scholar : PubMed/NCBI
|
45
|
Emre M, Aarsland D, Brown R, Burn DJ,
Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier
S, et al: Clinical diagnostic criteria for dementia associated with
Parkinson's disease. Mov Disord. 22:1689–1707. 2007. View Article : Google Scholar : PubMed/NCBI
|
46
|
Litvan I, Goldman JG, Tröster AI, Schmand
BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K,
Williams-Gray CH, et al: Diagnostic criteria for mild cognitive
impairment in Parkinson's disease: Movement Disorder Society Task
Force guidelines. Mov Disord. 27:349–356. 2012. View Article : Google Scholar : PubMed/NCBI
|
47
|
Gyoneva S, Shapiro L, Lazo C,
Garnier-Amblard E, Smith Y, Miller GW and Traynelis SF: Adenosine
A2A receptor antagonism reverses inflammation-induced impairment of
microglial process extension in a model of Parkinson's disease.
Neurobiol Dis. 67:191–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
48
|
Deleidi M and Gasser T: The role of
inflammation in sporadic and familial Parkinson's disease. Cell Mol
Life Sci. 70:4259–4273. 2013. View Article : Google Scholar : PubMed/NCBI
|
49
|
Fu SP, Wang JF, Xue WJ, Liu HM, Liu BR,
Zeng YL, Li SN, Huang BX, Lv QK, Wang W, et al: Anti-inflammatory
effects of BHBA in both in vivo and in vitro Parkinson inverted
question marks disease models are mediated by GPR109A-dependent
mechanisms. J Neuroinflammation. 12:92015. View Article : Google Scholar
|
50
|
Hirsch EC, Hunot S, Damier P and Faucheux
B: Glial cells and inflammation in Parkinson's disease: A role in
neurodegeneration? Ann Neurol. 44(Suppl 1): S115–S120. 1998.
View Article : Google Scholar : PubMed/NCBI
|
51
|
Kitamura Y, Itano Y, Kubo T and Nomura Y:
Suppressive effect of FK-506, a novel immunosuppressant, against
MPTP-induced dopamine depletion in the striatum of young C57BL/6
mice. J Neuroimmunol. 50:221–224. 1994. View Article : Google Scholar : PubMed/NCBI
|
52
|
Sriram K and O'Callaghan JP: Divergent
roles for tumor necrosis factor-alpha in the brain. J Neuroimmune
Pharmacol. 2:140–153. 2007. View Article : Google Scholar : PubMed/NCBI
|
53
|
Wang MJ, Huang HY, Chen WF, Chang HF and
Kuo JS: Glycogen synthase kinase-3β inactivation inhibits tumor
necrosis factor-α production in microglia by modulating nuclear
factor κB and MLK3/JNK signaling cascades. J Neuroinflammation.
7:992010. View Article : Google Scholar
|
54
|
Fu SP, Li SN, Wang JF, Li Y, Xie SS, Xue
WJ, Liu HM, Huang BX, Lv QK, Lei LC, et al: BHBA suppresses
LPS-induced inflammation in BV-2 cells by inhibiting NF-kappaB
activation. Mediators Inflamm. 2014:9834012014. View Article : Google Scholar
|
55
|
Bae GS, Kim MS, Jung WS, Seo SW, Yun SW,
Kim SG, Park RK, Kim EC, Song HJ and Park SJ: Inhibition of
lipopolysaccharide-induced inflammatory responses by piperine. Eur
J Pharmacol. 642:154–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
56
|
Lovell MA, Ehmann WD, Butler SM and
Markesbery WR: Elevated thiobarbituric acid-reactive substances and
antioxidant enzyme activity in the brain in Alzheimer's disease.
Neurology. 45:1594–1601. 1995. View Article : Google Scholar : PubMed/NCBI
|
57
|
Hirai K, Aliev G, Nunomura A, Fujioka H,
Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M,
et al: Mitochondrial abnormalities in Alzheimer's disease. J
Neurosci. 21:3017–3023. 2001.PubMed/NCBI
|
58
|
Lyras L, Perry RH, Perry EK, Ince PG,
Jenner A, Jenner P and Halliwell B: Oxidative damage to proteins,
lipids, and DNA in cortical brain regions from patients with
dementia with Lewy bodies. J Neurochem. 71:302–312. 1998.
View Article : Google Scholar : PubMed/NCBI
|
59
|
Olanow CW: The pathogenesis of cell death
in Parkinson's disease - 2007. Mov Disord. 22(Suppl 17): S335–S342.
2007. View Article : Google Scholar
|
60
|
Tatton WG and Olanow CW: Apoptosis in
neurodegenerative diseases: The role of mitochondria. Biochim
Biophys Acta. 1410:195–213. 1999. View Article : Google Scholar : PubMed/NCBI
|
61
|
Eskes R, Antonsson B, Osen-Sand A,
Montessuit S, Richter C, Sadoul R, Mazzei G, Nichols A and Martinou
JC: Bax-induced cytochrome C release from mitochondria is
independent of the permeability transition pore but highly
dependent on Mg2+ ions. J Cell Biol. 143:217–224. 1998.
View Article : Google Scholar : PubMed/NCBI
|
62
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
63
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|